转移性食管胃腺癌一线姑息系统治疗时机:人群分析与目标试验模拟
BACKGROUND: With increasing detection of asymptomatic or limited metastatic esophagogastric adenocarcinoma (mEAC), deferring systemic therapy may spare patients toxicity and hospital visits, but its impact on overall survival (OS) and health-related quality of life (HRQoL) is unc…
要点
- 延迟启动(>8周)与立即启动一线系统治疗的OS无临床相关差异,HR 0.91(95%CI 0.82–1.02)。
- 延迟组3个月时社交与角色功能可能更优、疲乏更少,HRQoL总体相当。
- 对预后良好特征的mEAC患者,延迟治疗可作为合理选项。
核心结论
- 在预后良好特征的转移性食管胃腺癌患者中,延迟启动一线系统治疗与立即启动相比未观察到临床相关的OS差异。
- 延迟启动组HRQoL总体与立即组相当,部分维度(社交/角色功能、疲乏)在3个月时可能更优。
研究设计与样本
- 基于荷兰癌症登记2010–2023年诊断为mEAC并接受一线系统治疗的患者进行人群分析。
- 采用目标试验模拟,限制为预后良好特征且两种策略均适用的患者,用逆概率治疗加权控制混杂。
- 采用8周界标分析处理不朽时间偏倚;HRQoL用EORTC QLQ-C30与OG25评估。
主要发现
- 自mEAC诊断后8周起中位OS:延迟组10.9个月(95%CI 9.59–11.86),立即组9.4个月(95%CI 8.90–9.89),HR 0.91(95%CI 0.82–1.02)。
- HRQoL总体可比,延迟组3个月时社交与角色功能可能更好、疲乏更少。
关键数值与推荐
- 立即治疗定义为诊断后≤8周启动,延迟定义为>8周启动。
- 目标试验模拟限定预后良好特征且符合两种策略的患者。
- 中位OS从mEAC诊断后8周起算:延迟组10.9个月(95%CI 9.59–11.86),立即组9.4个月(95%CI 8.90–9.89),HR 0.91(95%CI 0.82–1.02)。
临床怎么用
- 对预后良好特征、无症状或局限转移的mEAC患者,可与患者共同决策考虑延迟启动一线系统治疗。
- 延迟期间需密切随访,及时评估疾病进展与症状出现。
局限性
- 研究为基于登记数据的目标试验模拟,非随机对照试验,可能存在残余混杂。
- 目标试验模拟仅纳入预后良好特征患者,结论不宜外推至所有mEAC患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With increasing detection of asymptomatic or limited metastatic esophagogastric adenocarcinoma (mEAC), deferring systemic therapy may spare patients toxicity and hospital visits, but its impact on overall survival (OS) and health-related quality of life (HRQoL) is unclear. METHODS: Patients diagnosed with mEAC between 2010 and 2023 and treated with first-line systemic therapy were identified from the Netherlands Cancer Registry. Immediate treatment was defined as starting ≤ 8 weeks after diagnosis and deferred as > 8 weeks. We emulated a target trial, restricting to patients with prognostically favourable characteristics eligible for both strategies, to compare OS and HRQoL using inverse probability of treatment weighting to mitigate confounding. An 8-week landmark analysis addressed immortal time bias. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 (QLQ-C30) and Esophagogastric 25 (OG25). RESULTS: Among 7.380 patients, median time to systemic therapy was 29 days (range 0-824 days); 1.162 patients (16%) had a deferred start. 2.812 (35%) patients were eligible for the emulated target trial (494 deferred, 2.318 immediate). No clinically relevant OS difference was observed (median OS from 8 weeks after mEAC diagnosis: 10.9 months (95%CI 9.59-11.86) in the deferred group versus 9.4 months (95%CI 8.90-9.89) in the immediate group; HR 0.91 (95%CI 0.82-1.02)). HRQoL was generally comparable, with some indication of better social and role functioning and less fatigue at 3 months in the deferred start group. CONCLUSIONS: Our findings suggest that deferring could be a reasonable option in selected patients with prognostically favourable characteristics.
引用
- Kamp D, May AM, Kessels R, et al. Timing of first-line palliative systemic therapy in metastatic esophagogastric adenocarcinoma: A population-based analysis & target trial emulation. Eur J Cancer. 2026. PMID: 42826439. doi:10.1016/j.ejca.2026.117444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。